A dual-targeting oncolytic adenovirus Ad5/3-hTERT-CD40L (CGTG-401) has achieved encouraging effects in clinical studies [24], while an oncolytic adenovirus carrying the fusion protein of tumor antigen and CD40L also effectively activated dendritic cells (DC) and inhibited the growth of prostate cancer [25]. Here, CD40LG is linked to prostate carcinoma.